Apellis Stock Is Trading Higher On FDA Approval For Empaveli In Rare Blood Disorder

by Vandana Singh, Benzinga Editor

May 17, 2021 7:23 AM | 1 min read | Make a Comment

The FDA has approved Apellis Pharmaceuticals Inc's APLS Empaveli (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).
PNH is a rare blood disease that causes red blood cells to break apart because the surface of a person's blood cells is missing a protein that protects them from the body's immune system.
The drug is approved for use in adults with PNH who are treatment naïve and patients switching from the C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab).
The company says Empaveli is the first and only targeted C3 therapy for PNH.
Price Action: APLS shares are up 10.7% at $49 during the premarket session on the last check Monday.

Posted In: Biotech News Health Care FDA General Briefs Paroxysmal Nocturnal Hemoglobinuria

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.